Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Ilias Biologics Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This action is under the review of 1 distinct examiner, HAMA, JOANNE, within 1 distinct art unit. The 1 pending office action represents the company's current active prosecution in the Biotechnology & Pharmaceuticals sector.
HAMA, JOANNE is the busiest examiner for the company, managing 1 pending office action. Because the portfolio only has 1 distinct examiner, the entirety of the pending workload is concentrated with this one individual. This indicates a very specific focus for the company's current intellectual property efforts within its technology area.
Practitioners should observe that the 1 distinct examiner handles the entire pending inventory, which allows for a consistent prosecution path. The presence of 1 distinct art unit suggests that the company's current filings are targeted toward a specific technical niche. This 1 pending office action is the sole matter currently requiring attention from the patent office for this entity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506575 | Compositions Containing Protein Loaded Exosome and Methods for Preparing and Delivering the Same | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506575 | Compositions Containing Protein Loaded Exosome and Methods for Preparing and Delivering the Same | HAMA, JOANNE | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506575 | Compositions Containing Protein Loaded Exosome and Methods for Preparing and Delivering the Same | HAMA, JOANNE | 1647 | DP | Non-Final OA | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIlias Biologics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joanne Hama has the most, with 1 of Ilias Biologics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
